Insights - The U.S. FDA has filed Sarepta Therapeutics’ (SRPT) eteplirsen New Drug Application, starting the clock on a 6-month review of the drug. The FDA will make an … Continue Reading
Read nowInsights - Biopharma investors are in a funny spot. Where small/mid-cap biotech and pharma stocks have been pulling back for over a month now, the broader markets … Continue Reading
Read nowResearch - It’s been “risk-off” in equities this week as traders begin to factor in a rate hike from the Fed, and the high-beta biotech sector has … Continue Reading
Read nowInsights - To say that Biogen (BIIB) disappointed in a big way on Friday would be an understatement. With its second quarter earnings release on Friday morning … Continue Reading
Read nowInsights - Second quarter earnings from the large, publicly traded biopharma and specialty pharma companies begin to trickle out on Thursday, July 23. Below is your cheat sheet … Continue Reading
Read nowResearch - AFMD is up nearly 200% in less than two months. Taking profit is already a crowding trade on Monday, but we want to be doing … Continue Reading
PremiumInsights - The prettiest girl at the ball, Receptos (RCPT), went home with a handsome suitor this week. Celgene (CELG) is paying $7.2 billion, or $232 per … Continue Reading
Read now
